文献速递淋巴瘤

BCR信号抑制剂在慢性淋巴细胞白血病免疫调节中的新兴作用

Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2017-09-26

本文综述了靶向B细胞受体(BCR)信号通路的已批准药物(如伊布替尼和艾代拉利布)在慢性淋巴细胞白血病(CLL)中通过直接作用于恶性B细胞生存通路外,还对T细胞产生毒性并可能控制疾病。通过聚焦BCR信号抑制剂对T细胞区室的影响,可深入理解全身治疗的生物学结局,预测毒性或不良事件,并识别新的联合治疗方案。综述提示BCR抑制剂可能具有新的作用机制,为其扩展至其他癌症和自身免疫性疾病提供依据。

要点

  • BCR信号抑制剂(伊布替尼、艾代拉利布)除直接作用于恶性B细胞外,还影响CLL中的T细胞并介导毒性。
  • CLL T细胞协调免疫功能障碍和免疫相关并发症。
  • BCR抑制剂可能具有新的作用机制,为其用于其他癌症和自身免疫性疾病提供依据。

核心结论

  • 综述提示BCR抑制剂可能具有新的作用机制,为其扩展至其他癌症和自身免疫性疾病提供依据。

研究设计与样本

  • 综述,回顾临床前模型和患者样本中T细胞异常以及临床可用小分子BCR信号抑制剂对免疫细胞(尤其是T细胞)的影响。

主要发现

  • CLL T细胞协调免疫功能障碍和免疫相关并发症。
  • 已批准靶向BCR信号通路的药物(如伊布替尼和艾代拉利布)通过直接作用于恶性B细胞的关键生存通路显示活性。
  • 这些药物还对CLL中的T细胞产生毒性并可能控制疾病。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approved therapies that target the B-cell receptor (BCR) signaling pathway, such as ibrutinib and idelalisib, are known to show activity in chronic lymphocytic leukemia (CLL) via their direct effects on crucial survival pathways in malignant B cells. However, these therapies also have effects on T cells in CLL by mediating toxicity and possibly controlling disease. By focusing on the effects of BCR signaling inhibitors on the T-cell compartment, we may gain new insights into the comprehensive biological outcomes of systemic treatment to further understand mechanisms of drug efficacy, predict the toxicity or adverse events, and identify novel combinatorial therapies. Here, we review T-cell abnormalities in preclinical models and patient samples, finding that CLL T cells orchestrate immune dysfunction and immune-related complications. We then continue to address the effects of clinically available small molecule BCR signaling inhibitors on the immune cells, especially T cells, in the context of concomitant immune-mediated adverse events and implications for future treatment strategies. Our review suggests potentially novel mechanisms of action related to BCR inhibitors, providing a rationale to extend their use to other cancers and autoimmune disorders.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Maharaj K, Sahakian E, Pinilla-Ibarz J, et al. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia. Blood Adv. 2017. PMID: 29296833. doi:10.1182/bloodadvances.2017006809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。